FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor
outcome despite intensive chemotherapy. The only curative option is thought to be allogeneic
hematopoietic stem cell transplantation (HSCT) in remission.
This phase II study is aimed to evaluate the efficacy of Olverembatinib, consolidated with
HSCT in the treatment of FGFR1-rearranged myeloid/lymphoid neoplasm.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University